Daiichi Sankyo Inc patent expiration

1. Savaysa patent expiration

SAVAYSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7365205 DAIICHI SANKYO INC Diamine derivatives
Apr, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition
Mar, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2020
M(M-243) Aug 09, 2022
M(M-14) Oct 18, 2026

Drugs and Companies using EDOXABAN TOSYLATE ingredient

NCE-1 date: 08 January, 2019

Market Authorisation Date: 08 January, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of SAVAYSA before it's drug patent expiration?
More Information on Dosage

SAVAYSA family patents

Family Patents

2. Turalio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(8 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(11 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity
Apr, 2028

(3 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(8 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(11 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 02, 2024
Orphan Drug Exclusivity(ODE-250) Aug 02, 2026
ODE*(ODE*) Aug 02, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 August, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE

More Information on Dosage

TURALIO family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Vanflyta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8883783 DAIICHI SANKYO INC Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Mar, 2027

(2 years from now)

US7820657 DAIICHI SANKYO INC Imidazolothiazole compounds for the treatment of disease
Sep, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557810 DAIICHI SANKYO INC Imidazolothiazole compounds for the treatment of disease
Mar, 2027

(2 years from now)

US8129374 DAIICHI SANKYO INC Method of using imidazolothiazole compounds for the treatment of disease
Mar, 2027

(2 years from now)

US9585892 DAIICHI SANKYO INC Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Mar, 2027

(2 years from now)

US8865710 DAIICHI SANKYO INC Methods of treating proliferative diseases
Aug, 2029

(5 years from now)

US7968543 DAIICHI SANKYO INC Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
Aug, 2029

(5 years from now)

US8836218 DAIICHI SANKYO INC Methods of treatment using combination therapy
Mar, 2030

(5 years from now)

US9555040 DAIICHI SANKYO INC Methods of treating proliferative diseases
May, 2030

(5 years from now)

US8357690 DAIICHI SANKYO INC Methods of treatment using combination therapy
Feb, 2031

(6 years from now)

US9675549 DAIICHI SANKYO INC Tablet containing composite with cyclodextrin
Sep, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2028
Orphan Drug Exclusivity(ODE-437) Jul 20, 2030

Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 21 July, 2027

Market Authorisation Date: 20 July, 2023

Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...

Dosage: TABLET

More Information on Dosage

VANFLYTA family patents

Family Patents